Pathogenic streptococci

Pathogenic streptococci represent a diverse group of Gram-positive, chain-forming bacteria that include major human pathogens such as Streptococcus pyogenes (Group A), Streptococcus agalactiae (Group B), and Streptococcus pneumoniae (StatPearls, 2023). These organisms are characterized by their hemolytic properties and Lancefield classification, playing critical roles in diseases ranging from superficial skin infections and pharyngitis to invasive conditions like sepsis, meningitis, and toxic shock syndrome (CDC, 2022). While the term refers to a biological category of organisms rather than a single molecular target, therapeutic strategies focus on specific bacterial components, such as penicillin-binding proteins (PBPs) involved in cell wall peptidoglycan synthesis or the bacterial ribosome to halt protein production (NIH, 2021). Effective management typically relies on antibiotics like beta-lactams, macrolides, and glycopeptides. However, the emergence of multi-drug resistant strains, particularly in S. pneumoniae, poses a significant global health threat and complicates empirical treatment (WHO, 2020). Diagnostic identification often utilizes biomarkers like the anti-streptolysin O (ASO) titer or rapid antigen detection tests to guide clinical intervention and monitor post-streptococcal complications like rheumatic fever.

Other names

StreptococcusStrep bacteriaGroup A StreptococcusGroup B StreptococcusPneumococcusViridans streptococci

Antibiotics targeting these organisms typically act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), or by inhibiting protein synthesis through binding to the 50S or 30S ribosomal subunits.